IPO Is Next Finance Target For Hookipa Biotech After $60m Series C
Executive Summary
Emerging Company Profile: Austria's privately-held Hookipa Biotech just raised $60m to progress two proof of concept clinical trials for its lead development programs. It will eventually seek a public listing.
You may also be interested in...
Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases
Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.
BioNotebook: Tonix, XenoPort offerings; Ophthotech royalty financing; UniQure, Achaogen IPOs
At the end of a rocky week for the stock market, including biotechnology stocks, it was not surprising to see shares of Tonix Pharmaceuticals and XenoPort lose some value on 24 January after the companies priced separate stock offerings. The declines brought their stocks in line with their offerings, which were priced below the prior day's market values.
Austrian start-up Hookipa raises €7 million in series A round
Austrian start-up company, Hookipa Biotech, has raised €7 million in a series A financing round led by Sofinnova Partners. Forbion Capital Partners also joined the syndicate as a co-investor.